IOVANCE BIOTHERAPEUTICS, INC. 8-K

What Happened
Iovance Biotherapeutics, Inc. (IOVA) filed a Form 8-K reporting that board member Wendy Yarno notified the company on March 17, 2026 that she will retire from the Board and will not stand for re-election at the company’s annual meeting, which is currently anticipated to be held in June 2026. Ms. Yarno will continue to serve as a director until the Annual Meeting. The filing (Item 5.02) states her decision is not due to any disagreement with the company’s operations, policies, or practices.

Key Details

• Notice given by Wendy Yarno on March 17, 2026; Form 8-K filed March 20, 2026 (Item 5.02).
• Ms. Yarno will serve through the Annual Meeting currently anticipated in June 2026.
• Iovance states the retirement is not the result of any disagreement with the company.
• The company publicly thanked Ms. Yarno for her service on the Board.

Why It Matters
This is a board-level personnel change that affects corporate governance but not the company’s day-to-day operations or financial results. Because the departure is voluntary and not due to a disagreement, it lowers the likelihood of immediate governance concerns. Shareholders should watch for proxy filings or announcements about any nominee to fill her seat ahead of the annual meeting, as board composition can influence strategic oversight.